Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS (UTHR) Form 144 notice reports a proposed sale of 4,000 common shares through TD Securities (USA) LLC on 09/17/2025, with an aggregate market value of $1,600,686.85. The securities were originally acquired on 03/15/2016 as part of an executive deferred compensation arrangement from Martine Rothblatt, totaling 294,000 shares acquired on that date and paid via vested options settled in common shares. The filing lists the company’s outstanding shares as 45,230,000.
The notice also discloses six sales by Martine Rothblatt during 09/09–09/16/2025 totaling 28,000 shares with gross proceeds shown for each sale. The filer represents they are not aware of undisclosed material adverse information and certifies compliance with Rule 144 procedures.
Michael Benkowitz, President and COO of United Therapeutics (UTHR), reported multiple transactions dated 09/15/2025 involving the exercise of stock options and subsequent sales of resulting common shares held in trusts. The filing shows the exercise of 14,625 options at a $135.42 exercise price and 7,875 options at a $146.03 exercise price, converting into shares held in trusts for which the reporting person is a beneficiary or has sole investment and voting power.
The sold shares were executed under a Rule 10b5-1 trading plan established on June 3, 2025, and were sold in multiple trades at weighted average prices reported between approximately $396.44 and $403.51 per share (ranges disclosed per trade group). The Form 4 discloses the trust arrangements and that transactions were effected in multiple trades with weighted-average prices disclosed in explanatory footnotes.
United Therapeutics Form 144 (Rule 144) filing by Martine Rothblatt: The filing notifies proposed sales of 4,000 common shares via TD Securities on 09/16/2025 with an aggregate market value of $1,601,062.04. The shares were originally acquired on 03/15/2016 under an executive deferred compensation arrangement (294,000 shares acquired then) and were exercised via vested options with payment made in common shares. The filer reported multiple prior sales in September 2025 totaling 20,000 shares and gross proceeds shown for each trade.
United Therapeutics (UTHR) insider activity: Martine A. Rothblatt, Chairperson & CEO, executed a pre-arranged 10b5-1 plan and on 09/12/2025 and 09/15/2025 exercised stock options and sold shares. The filing shows two option exercises of 4,000 options each (total 8,000 options) at an exercise price of $120.26, resulting in acquisitions of 4,000 shares on each date. Concurrently, the reporting person sold 4,000 shares on 09/12/2025 and 4,000 shares on 09/15/2025 at weighted average prices in the low $400s, for total reported sales of 8,000 shares. The form discloses substantial additional holdings indirectly: trusts and spouse holdings totaling hundreds of thousands of shares and a tranche of 294,000 options expiring 03/15/2026 under the 10b5-1 plan.
UNITED THERAPEUTICS (UTHR) Form 144 shows a proposed sale of 4,000 common shares through TD Securities on NASDAQ with an aggregate market value of $1,591,535.70. The filer reports acquiring 294,000 shares on 03/15/2016 under an executive deferred compensation arrangement, where shares were issued via vested option exercises and payment made in common shares. The filing also discloses recent open-market sales by Martine Rothblatt totaling 20,000 shares across 09/09–09/12/2025 with combined gross proceeds reported on each trade. The notice includes the standard insider representation about lack of undisclosed material information.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corporation (UTHR), reported option exercises and concurrent sales under a pre-arranged 10b5-1 trading plan. On 09/10/2025 and 09/11/2025 she exercised 4,000 stock options each day at an exercise price of $120.26 per share, resulting in 8,000 shares acquired. Those 8,000 shares were sold the same two days in multiple trades at weighted-average prices of approximately $397–$399, generating the reported sales of 8,000 shares.
Following these transactions, the filing shows direct beneficial ownership lines with small net share changes and indicates remaining stock options outstanding: 282,000 and 278,000 shown after the two exercises, and a tranche of 294,000 options subject to the 10b5-1 plan that expire on March 15, 2026. The 10b5-1 plan was entered May 2, 2025 and will continue until the tranche is exhausted or December 31, 2025.
United Therapeutics Corp (UTHR) Form 144: This notice shows that Martine Rothblatt proposes to sell 4,000 common shares through TD Securities (125 Park Ave, 20th Floor, New York) with an aggregate market value of $1,588,904.00, scheduled approximately for 09/11/2025. The issuer has 45,230,000 shares outstanding, per the filing.
The shares were originally acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt, with 294,000 shares shown as acquired then. The filing also reports recent sales by the same person in the past three months: 8,000 shares sold on 09/09/2025 for $3,188,374.33 and 4,000 shares sold on 09/10/2025 for $1,594,872.82. The filer attests there is no undisclosed material adverse information.
United Therapeutics (UTHR) Form 144 notice shows a proposed sale of 4,000 common shares through TD Securities on 09/10/2025, with an aggregate market value of $1,594,872.82. The filing reports 45,230,000 shares outstanding, providing context for the size of the proposed sale relative to the company’s float.
The securities being sold were originally acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt (amount acquired: 294,000). The filing also discloses a recent sale of 8,000 shares on 09/09/2025 that generated gross proceeds of $3,188,374.33. Payment for the acquired securities was by shares exercised via vested options and paid with common shares.
United Therapeutics insider filings show option exercises and planned sales under a Rule 10b5-1 plan. Michael Benkowitz, President and COO, executed stock option exercises on September 8-9, 2025 that resulted in acquisitions of common stock and contemporaneous sales from trusts he controls or co-trustees. The filing discloses option exercises (aggregate of 22,500 underlying shares across grants) and multiple sales at weighted-average prices ranging roughly from $389.45 up to $400.51. The transactions were executed pursuant to a 10b5-1 plan entered June 3, 2025. The filing identifies the shares and options as beneficially owned indirectly via trusts for which the reporting person serves as trustee or beneficiary.
Malcolm Jan, a director of United Therapeutics Corp (UTHR), reported a single transaction disposing of 700 shares of the issuer's common stock on 09/09/2025 at a reported price of $400.29 per share. After this sale the filing shows 520 shares beneficially owned by Mr. Jan in a direct ownership form. The Form 4 was filed as a single reporting person disclosure and identifies the reporting relationship as Director.